David Young
Co-Founder, President of Research and Development & DirectorDr. David Young, Pharm.D., Ph.D., is Member of Scientific Advisor of GEn1E Lifesciences Inc. He is the Co-Founder of Processa Pharmaceuticals, Inc. since 2017. He served as an Interim Chief Financial Officer at Processa Pharmaceuticals, Inc until 2022. He served as Chairman at Processa Pharmaceuticals, Inc since October 04, 201 until July 2022 and served as its Chief Executive Officer since October 04, 2017 until August 2023 and served as its President. He served as President of Processa Pharmaceuticals, Inc. since July 2022 until August 2023. He served as Interim Chief Financial Officer at Processa Pharmaceuticals, Inc. from October 04, 2017 until September 1, 2018. He serves as Director of Processa Pharmaceuticals, Inc. since October 04, 2017 and has been its President, Research and Development since August 08, 2023. He serves as the Chairman of the Board and Interim Chief Financial Officer of Heatwurx, Inc. and has been its Chief Executive Officer and Director since October 4, 2017. Dr. Young has several years of pharmaceutical research, drug development and corporate expertise. He was a Founder and Chief Executive Officer of Processa Pharmaceuticals, Inc (Formerly known as Promet Therapeutics, LLC) since its formation in August 2015. Dr. Young served as the Chief Scientific Officer of Questcor Pharmaceuticals, Inc. from October 30, 2009 to 2014. Dr. Young served as President of US Operations of AGI Therapeutics plc. He served as the President of AGI Therapeutics inc. He served as an Executive Vice President of ICON Development Solutions, which is the Strategic Pharmaceutical Development Division of ICON PLC, an international CRO. He co-founded ICON Development Solutions (formerly, Globomax LLC) in 1997 and was responsible for developing and directing its scientific and business missions. He served as the President and Chief Executive Officer of Globomax LLC until September 2003 when it was acquired by ICON PLC. From 1991 to June 1997, Dr. Young served as Director of the Pharmacokinetics of Biopharmaceutics Laboratory (PBL) at the University of Maryland at Baltimore (UMAB) and an Associate Professor in the Department of Pharmaceutical Sciences and the Department of Pharmacy Practice and Science. In 1982, he became an Assistant Professor at the University of Texas and in 1986, he moved to the University of Maryland served as Managing Director of the University of Maryland-VA Clinical Research Unit. He has worked with more than 50 different pharmaceutical companies performing population, Bayesian and IVIVC analysis for NDA/sNDA applications and addressing specific questions associated with NDA/sNDA applications or labeling. Dr. Young serves as Project Leader for the IVIVR Cooperative Working Group within the Pharmaceutical Industry, Group Leader for clinical research and IVIVC in the FDA/UMAB Collaborative Manufacturing Agreement and Principal Investigator for the FDA/UMAB Clinical Facility Collaborative Agreement and an FDA Advisory Board Member. He has been a Director of LifeScience PLUS, Inc., since June 2012. Dr. Young is an expert in small molecule and protein non-clinical and clinical drug development. He served as a Non-Executive Director of AGI Therapeutics plc until December 31, 2010. He served as an Executive Director and President of AGI Therapeutics Plc and Director of AGI Therapeutics Inc. He served as a Director of Questcor Pharmaceuticals, Inc. from September 27, 2006 to 2009. His personal research interests are in developing the scientific and regulatory strategies for product development. He has a broad range of regulatory science expertise from the use of mathematical, statistical and population modeling techniques in drug development and regulatory science to clinical study design. Dr. Young has represented more than 30 sponsors at the Food and Drug Administration (FDA), worked on more than 70 drug products and been involved with more than 30 NDA submissions. He was Co-Principal Investigator on an FDA-funded Clinical Pharmacology contract and was also Co-Principal Investigator on a National Cancer Institute contract to evaluate new oncology drugs. He has an extensive background in drug development that includes more than 150 presentations and authored publications, including formal presentations to the FDA and numerous invited presentations at scientific meetings. He is an expert in 505(b)(2) drug development, having worked on more than 25 programs in various therapeutic areas including Central Nervous System (CNS) diseases and disorders. He received his Pharm.D. - Ph.D. from the University of Southern California in 1981 and 1982, specializing in Pharmacokinetics and Pharmaceutical Sciences. Dr. Young holds a B.S. degree in Physiology from the University of California, Berkeley, an M.S. degree in Medical Physics from the University of Wisconsin Madison.
Positions
- Company NameProcessa Pharmaceuticals, Inc.Stock CodePCSAPositionCo-Founder, President of Research and Development & Director
